Abstract
Obesity continues to pose an urgent public health challenge in the United States, with prevalence among adults and significant associations with chronic conditions, including diabetes, cardiovascular disease, and nonalcoholic fatty liver disease. While bariatric surgery has established itself as the most effective long-term treatment for severe obesity, delivering consistent weight loss and notable improvements in obesity-related comorbidities, its utilization remains relatively low due to factors such as patient apprehension, access disparities, and insurance limitations. The recent emergence and widespread adoption of potent anti-obesity medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin agonists such as tirzepatide, have created new, non-surgical pathways capable of achieving substantial weight loss outcomes, thus prompting a reevaluation of the traditional obesity treatment landscape. This comprehensive review assesses the contemporary state of bariatric surgery and systematically examines the clinical efficacy, safety, and durability of emerging pharmacotherapies relative to surgical interventions. We also analyze the potential implications of these medications on patient preferences, surgical volumes, healthcare economics, and the bariatric surgery job market within the United States. Recognizing the evolving role of bariatric surgeons, we discuss how the profession may adapt through multidisciplinary care models, integrated pharmacological management, and adjusted surgical training programs. The goal of this manuscript is to inform clinicians, healthcare systems, policymakers, and patients regarding the anticipated impact of novel weight-loss medications on the future direction of obesity care and the professional landscape of bariatric surgery.